Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of rivaroxaban in the prevention of atherosclerotic events.
Sanmartín M, Bellmunt S, Cosín-Sales J, García-Moll X, Riera-Mestre A, Almendro-Delia M, Hernández JL, Lozano F, Mazón P, Suarez Fernández C. Sanmartín M, et al. Among authors: suarez fernandez c. Expert Rev Clin Pharmacol. 2019 Aug;12(8):771-780. doi: 10.1080/17512433.2019.1637732. Epub 2019 Jul 9. Expert Rev Clin Pharmacol. 2019. PMID: 31269825 Review.
Adherence to recommendations of the Therapeutic Positioning Report about treatment with oral anticoagulants in elderly patients with atrial fibrillation. The ESPARTA study.
Suárez Fernández C, Mostaza JM, Castilla Guerra L, Cantero Hinojosa J, Suriñach JM, Acosta de Bilbao F, Tamarit JJ, Diaz Diaz JL, Hernandez JL, Cazorla D, Ràfols C; en nombre de los Investigadores del Estudio ESPARTA. Suárez Fernández C, et al. Med Clin (Barc). 2018 Jul 13;151(1):8-15. doi: 10.1016/j.medcli.2017.07.025. Epub 2017 Oct 6. Med Clin (Barc). 2018. PMID: 28992980 English, Spanish.
Satisfaction with oral anticoagulants in patients with atrial fibrillation.
Suárez Fernández C, Castilla-Guerra L, Cantero Hinojosa J, Suriñach JM, Acosta de Bilbao F, Tamarit JJ, Diaz Diaz JL, Hernandez JL, Pose A, Montero-Pérez-Barquero M, Roquer J, Gállego J, Vivancos J, Mostaza JM. Suárez Fernández C, et al. Patient Prefer Adherence. 2018 Feb 19;12:267-274. doi: 10.2147/PPA.S152109. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 29497282 Free PMC article.
Rivaroxaban: searching the integral vascular protection.
Barrios V, Almendro-Delia M, Facila L, Garcia-Moll X, Mazón P, Camafort M, Cepeda JM, Mediavilla Garcia JD, Pose Reino A, Suarez Fernandez C. Barrios V, et al. Among authors: suarez fernandez c. Expert Rev Clin Pharmacol. 2018 Jul;11(7):719-728. doi: 10.1080/17512433.2018.1495559. Epub 2018 Jul 18. Expert Rev Clin Pharmacol. 2018. PMID: 29965791 Review.
Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition.
González-Juanatey JR, Almendro-Delia M, Cosín-Sales J, Bellmunt-Montoya S, Gómez-Doblas JJ, Riambau V, García-Moll X, García-Alegría J, Hernández JL, Lozano FS, Suarez Fernández C. González-Juanatey JR, et al. Among authors: suarez fernandez c. Expert Rev Clin Pharmacol. 2020 Jul;13(7):695-706. doi: 10.1080/17512433.2020.1772056. Expert Rev Clin Pharmacol. 2020. PMID: 32434452 Review.
Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial.
Hernández JL, Lozano FS, Riambau V, Almendro-Delia M, Cosín-Sales J, Bellmunt-Montoya S, Garcia-Alegria J, Garcia-Moll X, Gomez-Doblas JJ, Gonzalez-Juanatey JR, Suarez Fernández C. Hernández JL, et al. Among authors: suarez fernandez c. Drugs Context. 2020 Jul 6;9:2020-5-5. doi: 10.7573/dic.2020-5-5. eCollection 2020. Drugs Context. 2020. PMID: 32699549 Free PMC article. Review.
Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.
Mostaza JM, Suárez-Fernández C, Cosín-Sales J, Gómez-Huelgas R, Brotons C, Araujo FP, Borrayo G, Ruiz E; VULCANO investigators. Mostaza JM, et al. Among authors: suarez fernandez c. BMC Cardiovasc Disord. 2022 Dec 22;22(1):560. doi: 10.1186/s12872-022-03013-w. BMC Cardiovasc Disord. 2022. PMID: 36550424 Free PMC article. Clinical Trial.
[Association of antiagregants: when and how].
López Menchaca R, Herrero Martínez JM, Suárez Fernández C. López Menchaca R, et al. Among authors: suarez fernandez c. Med Clin (Barc). 2007 Mar 17;128(10):383-9. doi: 10.1157/13099977. Med Clin (Barc). 2007. PMID: 17386246 Review. Spanish.
Impact of comprehensive and intensive treatment of risk factors concerning cardiovascular mortality in secondary prevention: MIRVAS Study.
Moreno-Palanco MA, Ibáñez-Sanz P, Ciria-de Pablo C, Pizarro-Portillo A, Rodríguez-Salvanés F, Suárez-Fernández C. Moreno-Palanco MA, et al. Among authors: suarez fernandez c. Rev Esp Cardiol. 2011 Mar;64(3):179-85. doi: 10.1016/j.recesp.2010.07.009. Epub 2011 Feb 16. Rev Esp Cardiol. 2011. PMID: 21330034 Free article. Clinical Trial.
[Practical issues with the use of rivaroxaban].
Suárez-Fernández C, Roldán V, Vivancos J. Suárez-Fernández C, et al. Rev Neurol. 2013 Nov 1;57(9):411-21. Rev Neurol. 2013. PMID: 24150953 Free article. Review. Spanish.
111 results